BACKGROUND: Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups. This study addresses this issue by examining whether adolescent MDD with and without melancholic features (M-MDD and NonM-MDD) have distinct biological features in the kynurenine pathway (KP). The KP is initiated by pro-inflammatory cytokines via induction of the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan (TRP) into kynurenine (KYN). KYN is further metabolized into neurotoxins linked to neuronal dysfunction in MDD. Hypotheses were that, compared to healthy controls and to NonM-MDD adolescents, adolescents with M-MDD would exhibit: (i) increased activation of the KP [i.e., increased KYN and KYN/TRP (reflecting IDO activity)]; (ii) greater neurotoxic loads [i.e., increased 3-hydroxyanthranilic acid (3-HAA, neurotoxin) and 3-HAA/KYN (reflecting production of neurotoxins)]; and (iii) decreased TRP. We also examined relationships between severity of MDD and KP metabolites. METHODS: Subjects were 20 adolescents with M-MDD, 30 adolescents with NonM-MDD, and 22 healthy adolescents. MDD episode duration had to be >or= 6 weeks and Children's Depression Rating Scale-Revised (CDRS-R) scores were >or= 36. Blood samples were collected at AM after an overnight fast and analyzed using high-performance liquid chromatography. Group contrasts relied on analysis of covariance based on ranks, adjusted for age, gender, and CDRS-R scores. Analyses were repeated excluding medicated patients. Fisher's protected least significant difference was used for multiple comparisons. RESULTS: As hypothesized, KYN/TRP ratios were elevated and TRP concentrations were reduced in adolescents with M-MDD compared to NonM-MDD adolescents (p = .001 and .006, respectively) and to healthy controls (p = .008 and .022, respectively). These findings remained significant when medicated patients were excluded from the analyses. Significant correlations were obtained exclusively in the M-MDD group between KYN and 3-HAA/KYN and CDRS-R. CONCLUSIONS: Findings support the notion that adolescent M-MDD may represent a biologically distinct clinical syndrome.
BACKGROUND: Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups. This study addresses this issue by examining whether adolescent MDD with and without melancholic features (M-MDD and NonM-MDD) have distinct biological features in the kynurenine pathway (KP). The KP is initiated by pro-inflammatory cytokines via induction of the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan (TRP) into kynurenine (KYN). KYN is further metabolized into neurotoxins linked to neuronal dysfunction in MDD. Hypotheses were that, compared to healthy controls and to NonM-MDD adolescents, adolescents with M-MDD would exhibit: (i) increased activation of the KP [i.e., increased KYN and KYN/TRP (reflecting IDO activity)]; (ii) greater neurotoxic loads [i.e., increased 3-hydroxyanthranilic acid (3-HAA, neurotoxin) and 3-HAA/KYN (reflecting production of neurotoxins)]; and (iii) decreased TRP. We also examined relationships between severity of MDD and KP metabolites. METHODS: Subjects were 20 adolescents with M-MDD, 30 adolescents with NonM-MDD, and 22 healthy adolescents. MDD episode duration had to be >or= 6 weeks and Children's Depression Rating Scale-Revised (CDRS-R) scores were >or= 36. Blood samples were collected at AM after an overnight fast and analyzed using high-performance liquid chromatography. Group contrasts relied on analysis of covariance based on ranks, adjusted for age, gender, and CDRS-R scores. Analyses were repeated excluding medicated patients. Fisher's protected least significant difference was used for multiple comparisons. RESULTS: As hypothesized, KYN/TRP ratios were elevated and TRP concentrations were reduced in adolescents with M-MDD compared to NonM-MDD adolescents (p = .001 and .006, respectively) and to healthy controls (p = .008 and .022, respectively). These findings remained significant when medicated patients were excluded from the analyses. Significant correlations were obtained exclusively in the M-MDD group between KYN and 3-HAA/KYN and CDRS-R. CONCLUSIONS: Findings support the notion that adolescent M-MDD may represent a biologically distinct clinical syndrome.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: Vilma Gabbay; Rachel G Klein; Carmen M Alonso; James S Babb; Melissa Nishawala; Georgette De Jesus; Glenn S Hirsch; Pauline M Z Hottinger-Blanc; Charles J Gonzalez Journal: J Affect Disord Date: 2008-09-13 Impact factor: 4.839
Authors: M Maes; A Wauters; R Verkerk; P Demedts; H Neels; A Van Gastel; P Cosyns; S Scharpé; R Desnyder Journal: Neuropsychopharmacology Date: 1996-09 Impact factor: 7.853
Authors: Michael T Sapko; Paolo Guidetti; Ping Yu; Danilo A Tagle; Roberto Pellicciari; Robert Schwarcz Journal: Exp Neurol Date: 2005-08-15 Impact factor: 5.330
Authors: Aye-Mu Myint; Yong Ku Kim; Robert Verkerk; Simon Scharpé; Harry Steinbusch; Brian Leonard Journal: J Affect Disord Date: 2006-09-06 Impact factor: 4.839
Authors: John Curry; Paul Rohde; Anne Simons; Susan Silva; Benedetto Vitiello; Christopher Kratochvil; Mark Reinecke; Norah Feeny; Karen Wells; Sanjeev Pathak; Elizabeth Weller; David Rosenberg; Betsy Kennard; Michele Robins; Golda Ginsburg; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: M Maes; S Scharpé; H Y Meltzer; G Okayli; E Bosmans; P D'Hondt; B V Vanden Bossche; P Cosyns Journal: Psychiatry Res Date: 1994-11 Impact factor: 3.222
Authors: Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo Journal: J Psychiatr Res Date: 2015-05-19 Impact factor: 4.791
Authors: Rachel D Freed; Lushna M Mehra; Daniel Laor; Manishkumar Patel; Carmen M Alonso; Seunghee Kim-Schulze; Vilma Gabbay Journal: World J Biol Psychiatry Date: 2018-08-16 Impact factor: 4.132
Authors: Kailyn A L Bradley; Julia A C Case; Omar Khan; Thomas Ricart; Amira Hanna; Carmen M Alonso; Vilma Gabbay Journal: Psychiatry Res Date: 2015-04-01 Impact factor: 3.222